| Date | Title | Description |
| 15.07.2026 | Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis | HANGZHOU, China and SHANGHAI and BOSTON, July 15, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, toda... |
| 09.07.2026 | Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo | HANGZHOU, China, SHANGHAI and BOSTON, July 9, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today an... |
| 10.06.2026 | Lynk Pharmaceuticals' Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor | HANGZHOU, China, SHANGHAI and BOSTON, June 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, tod... |
| 01.06.2026 | Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema | HANGZHOU, China, SHANGHAI and BOSTON, June 1, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today an... |
| 02.03.2026 | Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis | SHANGHAI, HANGZHOU, China and BOSTON, March 2, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory dis... |
| 12.01.2026 | Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis | HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development company focused on developing inn... |
| 19.11.2025 | Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis | HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key r... |
| 13.08.2024 | Lynk Pharmaceuticals Announces Positive Results from Phase 1b Clinical Study of LNK01004 for the Treatment of Atopic Dermatitis | HANGZHOU, China and SHANGHAI and BOSTON, Aug. 13, 2024 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced positive re... |
| 22.03.2024 | Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001 | BOSTON and HANGZHOU and SHANGHAI, China, March 22, 2024 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced that it ha... |
| 20.12.2023 | Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001 | BOSTON and HANGZHOU and SHANGHAI, China, Dec. 20, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first patient w... |
| 26.09.2023 | Deals in brief: AnyMind Group acquires Indonesia-based DDI, GGV Capital splits into two businesses, eight China deals, and more | AnyMind Group acquires Digital Distribusi Indonesia
The Singapore-founded brand enablement company has acquired Digital Distribusi Indonesia (DDI), an Indonesia-based e-commerce enabler and distributor.
The acquisition will enable AnyMind G... |
| 21.09.2023 | Deals in brief: Bolttech extends Series B round, HSBC launches climate tech fund, seven new India deals, and more | Bolttech extends Series B round to record-breaking USD 246 million
The Singapore-headquartered insurtech company has extended its Series B round, raising USD 50 million from new strategic investor LeapFrog Investments. This investment adds ... |
| 21.09.2023 | Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB | HANGZHOU, China, Sept. 21, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, today announced the successful completion of Series C2 financing. This... |
| 21.09.2023 | Lynk Pharmaceuticals Completes Series C2 Financing | Lynk Pharmaceuticals, a Hangzhou, China-based clinical stage company, raised an undisclosed amount in Series C2 funding.
The round saw participation from Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund managed by China G... |
| 23.08.2023 | Lynk Pharmaceuticals Announces Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Ankylosing Spondylitis | HANGZHOU, China, Aug. 23, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (referred to as "Lynk Pharmaceuticals"), an innovative clinical stage company, announced positive topline data from a Phase II clinical trial of LNK0100... |
| 09.08.2023 | Lynk Pharmaceuticals Announced Positive Topline Data from Phase II Clinical Trial of LNK01001 in the Treatment of Atopic Dermatitis | HANGZHOU, China, Aug. 9, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced positive topline data from a Phase II clinical trial of LNK010... |
| 21.07.2023 | Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed with LNK01004 in Phase Ib Clinical Study | HANGZHOU, China, July 21, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first patient with atopic dermatitis in... |
| 01.06.2023 | Lynk Pharmaceuticals Completes 200M RMB Series C1 Financing | Lynk Pharmaceuticals, a Hangzhou, China-based clinical stage company, raised 200M RMB in Series C1 funding.
The round saw participation from China Grand Prosperity Investment, Tailong Capital and Liando Investment.
The company intends to us... |
| 31.05.2023 | Lynk Pharmaceuticals Completes 200 Million RMB Series C1 Financing to Accelerate Clinical Development of Core Products | HANGZHOU, China, May 31, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, today announced the successful completion of a RMB 200 million Series C1... |
| 25.05.2023 | Lynk Pharmaceuticals Announces First Cohort of Psoriatic Patients Dosed with LNK01004 in Phase Ib Clinical Study | HANGZHOU, China, May 25, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first cohort of psoriatic patients in a ... |
| 16.05.2023 | LYNK's LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis | HANGZHOU, China, May 16, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that the Phase II clinical trial of LNK01001 in the treatment ... |
| 04.04.2023 | Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects | HANGZHOU, China, April 4, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has recently completed phase I trials in healthy subj... |
| 05.12.2022 | Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis | HANGZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first patient in a Phase II clinical tri... |
| 03.08.2022 | Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China | HANGZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that its innovative drug LNK01004, has been approved by Nation... |
| 29.07.2022 | Lynk Pharmaceuticals Announces the First Participant Dosed in Phase I Trial of LNK01004 | HANGZHOU, China, July 29, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has completed dosing the first participant in the pha... |
| 22.04.2022 | Lynk Pharmaceuticals Announces Clinical Approval in China for Its Class I New Drug LNK01004 | HANGZHOU, China, April 22, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that its Class I innovative drug LNK01004, has been approved... |
| 18.03.2022 | Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership upon novel JAK1 inhibitor LNK01001 | HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor ... |
| 28.02.2022 | Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis | HANGZHOU, China, Feb. 28, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it had dosed the first patient with LNK01001 in its Phas... |
| 19.01.2022 | Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis | HANGZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced today that the first patient has been dosed with LNK01001 in ... |
| 01.12.2021 | Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001 | HANGZHOU, China, Dec. 1, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced the company has dosed the first patient with LNK01001 in its P... |
| 07.09.2021 | Digital health news, funding roundup in the prior week; September 6 | Whoop raised $200M and acquired PUSH; Cityblock landed $400M; Eight Sleep secured $86M
Push: Push is a personalized digital fitness and health coach. Whoop acquired PUSH for an undisclosed amount. Whoop makes a wearable that monitors sleep ... |
| 29.08.2021 | Lynk Pharmaceuticals Closes $50M Series B Financing | Lynk Pharmaceuticals CO., LTD, a Hangzhou, China-based pharmaceutical R&D company, completed Series B financing of $50m.
The round was led by Lilly Asia Ventures (LAV) with participation from New Alliance Capital and Hangzhou HEDA Biolo... |
| 27.08.2021 | Lynk Pharmaceuticals inks $50M series B for 3 early-stage trials | Lynk Pharmaceuticals picked up $50 million in series B funds Friday to bankroll three assets through phase 1 and 2 trials.
The Hangzhou, China-based biotech has received the green light to run clinical trials for three drugs in the U.S. and... |
| 27.08.2021 | Lynk Pharmaceuticals announced the completion of Series B financing of $50 million | HANGZHOU, China, Aug. 27, 2021 /PRNewswire/ -- Lynk Pharmaceuticals CO., LTD (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative pharmaceutical R&D company, today announced that it has successfully completed Ser... |
| 27.08.2021 | Lynk Pharmaceuticals inks $50M series B for 3 early-stage trials | Lynk Pharmaceuticals picked up $50 million in series B funds Friday to bankroll three assets through phase 1 and 2 trials.
The biotech also received clinical trial approval in China for its kinase inhibitor aimed at treating inflammatory bo... |
| 12.08.2021 | Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002 | HANGZHOU, China, Aug. 12, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative drug development company, announced today that it has administered its triple-kinase inhibitor ... |
| 25.06.2021 | Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003 | HANGZHOU, China, June 25, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative drug development company, announced today that its new Class I innovative drug LNK010... |
| - | LYNK Pharmaceuticals | “Lingke” |
